Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics.
Twenty-eight hypertensive patients on renal replacement therapy (HD, HF, PD) were treated with verapamil (Isoptin RR-slow release) in an open label study. Blood pressure was satisfactorily reduced in 21 patients (84%). Due to adverse reactions the treatment had to be discontinued in 4 patients. Verapamil clearances were calculated according to different dialysis methods. No changes in dose or mode of application of verapamil were necessary using any mode of renal replacement therapy.
Beyerlein
C
C
Medizinische Klinik III, Städtisches Krankenhaus, Kaiserslautern, FRG.
Csaszar
G
G
Hollmann
M
M
Schumacher
A
A
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D003692:Delayed-Action Preparations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006440:Hemofiltration; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008657:Metabolic Clearance Rate; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D014700:Verapamil